APA (7th ed.) Citation

Galvao, V., Palomero, J., Creus-Gonzalez, I., Lostes Bardaji, M., Lozano-Rabella, M., Garcia-Garijo, A., . . . Garralda, E. (2023). 1080TiP An investigator-initiated phase I study to assess the safety and tolerability of ex vivo next-generation neoantigen-selected tumor-infiltrating lymphocyte (TIL) therapy in advanced immune checkpoint blockade (ICB) resistant solid tumors (NEXTGENTIL-ACT). Annals of Oncology, 34, S650. https://doi.org/10.1016/j.annonc.2023.09.2977

Chicago Style (17th ed.) Citation

Galvao, V., et al. "1080TiP An Investigator-initiated Phase I Study to Assess the Safety and Tolerability of Ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Immune Checkpoint Blockade (ICB) Resistant Solid Tumors (NEXTGENTIL-ACT)." Annals of Oncology 34 (2023): S650. https://doi.org/10.1016/j.annonc.2023.09.2977.

MLA (9th ed.) Citation

Galvao, V., et al. "1080TiP An Investigator-initiated Phase I Study to Assess the Safety and Tolerability of Ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Immune Checkpoint Blockade (ICB) Resistant Solid Tumors (NEXTGENTIL-ACT)." Annals of Oncology, vol. 34, 2023, p. S650, https://doi.org/10.1016/j.annonc.2023.09.2977.